{"id":"tc-99m-pentetate","safety":{"commonSideEffects":[{"rate":null,"effect":"Minimal systemic adverse events (diagnostic agent with low toxicity)"},{"rate":null,"effect":"Radiation exposure (from Tc-99m decay)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tc-99m Pentetate (diethylenetriaminepentaacetic acid labeled with Technetium-99m) is a chelate complex that behaves as a freely filtered agent by the glomerulus. It does not bind to plasma proteins significantly and is rapidly cleared by the kidneys, making it ideal for assessing glomerular filtration rate, renal perfusion, and collecting system drainage. The gamma emissions from Tc-99m allow real-time imaging of renal function and detection of obstruction or impairment.","oneSentence":"Tc-99m Pentetate is a radiopharmaceutical that binds to transferrin in the blood and is filtered by the kidneys, allowing visualization of renal function and urinary tract anatomy via nuclear imaging.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T06:26:27.291Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Renal imaging and assessment of glomerular filtration rate"},{"name":"Detection of renal obstruction and urinary tract imaging"},{"name":"Evaluation of renal transplant function"}]},"trialDetails":[{"nctId":"NCT06982222","phase":"PHASE1","title":"Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-03-31","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma","enrollment":24},{"nctId":"NCT07159074","phase":"PHASE2","title":"Repurposing Tilmanocept for Cardiac Sarcoidosis","status":"RECRUITING","sponsor":"Duke University","startDate":"2025-09-17","conditions":"Cardiac Sarcoidosis","enrollment":15},{"nctId":"NCT07053696","phase":"PHASE1","title":"Pharmacokinetics, Safety, and Lung Deposition of 99mTc-DTPA Delivered Via the EDDIS System in Healthy Volunteers","status":"WITHDRAWN","sponsor":"Andrey Petrov","startDate":"2025-03-17","conditions":"Healthy Volunteers","enrollment":""},{"nctId":"NCT07121595","phase":"PHASE2","title":"Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial","status":"RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2025-07-17","conditions":"Oral Cavity Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8","enrollment":50},{"nctId":"NCT06116253","phase":"NA","title":"Advanced Diffusion Imaging in Renal Cancer Patients","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2022-12-01","conditions":"Renal Cancer","enrollment":90},{"nctId":"NCT03157167","phase":"PHASE1","title":"An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)","status":"COMPLETED","sponsor":"Navidea Biopharmaceuticals","startDate":"2017-12-01","conditions":"Kaposi Sarcoma, HIV Infections","enrollment":15},{"nctId":"NCT05246280","phase":"PHASE3","title":"Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA","status":"TERMINATED","sponsor":"Navidea Biopharmaceuticals","startDate":"2022-03-02","conditions":"Rheumatoid Arthritis","enrollment":169},{"nctId":"NCT04947137","phase":"PHASE2","title":"Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept","status":"COMPLETED","sponsor":"Navidea Biopharmaceuticals","startDate":"2021-05-27","conditions":"Rheumatoid Arthritis","enrollment":134},{"nctId":"NCT04078191","phase":"PHASE2","title":"Comparison of Tc 99m Tilmanocept Imaging With IHC Analysis of CD206 Expression in Synovial Tissue of Subjects With RA","status":"TERMINATED","sponsor":"Navidea Biopharmaceuticals","startDate":"2021-09-14","conditions":"Rheumatoid Arthritis","enrollment":20},{"nctId":"NCT03332940","phase":"PHASE1","title":"Safety Evaluation of IV Tc 99m Tilmanocept and Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH","status":"TERMINATED","sponsor":"Navidea Biopharmaceuticals","startDate":"2017-12-06","conditions":"Nonalcoholic Steatohepatitis, NASH - Nonalcoholic Steatohepatitis","enrollment":6},{"nctId":"NCT02509598","phase":"PHASE2","title":"A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping","status":"COMPLETED","sponsor":"Cardinal Health 414, LLC","startDate":"2015-08","conditions":"Rhabdomyosarcoma, Melanoma","enrollment":24},{"nctId":"NCT05236387","phase":"","title":"Evaluating the Ability of 99mTc-Tilmanocept to Identify Clipped Nodes in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy and Sentinel Lymph Node Dissection","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2022-03-01","conditions":"Breast Cancer","enrollment":14},{"nctId":"NCT02841371","phase":"","title":"Early Screening and Diagnosis of CKD","status":"UNKNOWN","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2009-08-01","conditions":"Kidney; Disease (Functional), Chronic Kidney Disease","enrollment":1000},{"nctId":"NCT04096716","phase":"PHASE1","title":"Mapping Draining Lymph Nodes in CNS Malignancies","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2019-12-03","conditions":"Central Nervous System Neoplasms, Central Nervous System Tumor","enrollment":14},{"nctId":"NCT04663126","phase":"EARLY_PHASE1","title":"Feasibility of IV Tc-99m-tilmanocept for Imaging of M2-like TAMs in Metastatic Melanoma","status":"TERMINATED","sponsor":"John O. Prior","startDate":"2021-02-01","conditions":"Melanoma","enrollment":5},{"nctId":"NCT00375830","phase":"PHASE2","title":"Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases","status":"COMPLETED","sponsor":"Stanford University","startDate":"2006-01","conditions":"Cancer","enrollment":114},{"nctId":"NCT04511026","phase":"PHASE2","title":"Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in Endometrial Cancer","status":"TERMINATED","sponsor":"Stanford University","startDate":"2021-01-20","conditions":"Endometrial Cancer","enrollment":6},{"nctId":"NCT03938636","phase":"PHASE2","title":"Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc 99m Tilmanocept Planar Imaging","status":"COMPLETED","sponsor":"Navidea Biopharmaceuticals","startDate":"2019-04-08","conditions":"Rheumatoid Arthritis","enrollment":116},{"nctId":"NCT02947126","phase":"PHASE1","title":"Multilevel Models of Therapeutic Response in the Lungs","status":"COMPLETED","sponsor":"Tim Corcoran","startDate":"2017-01","conditions":"Cystic Fibrosis","enrollment":56},{"nctId":"NCT03405142","phase":"PHASE2","title":"Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer","status":"COMPLETED","sponsor":"Eben Rosenthal","startDate":"2019-08-01","conditions":"Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Head and Neck Cancer","enrollment":3},{"nctId":"NCT02865434","phase":"PHASE1, PHASE2","title":"Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA","status":"COMPLETED","sponsor":"Navidea Biopharmaceuticals","startDate":"2017-01","conditions":"Arthritis, Rheumatoid","enrollment":39},{"nctId":"NCT03029988","phase":"PHASE1","title":"An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects With Liver Metastases.","status":"TERMINATED","sponsor":"Navidea Biopharmaceuticals","startDate":"2017-07-26","conditions":"Liver Metastases, Colorectal Carcinoma","enrollment":3},{"nctId":"NCT02287675","phase":"PHASE4","title":"Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer","status":"COMPLETED","sponsor":"Kettering Health Network","startDate":"2015-01-19","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT04240223","phase":"PHASE1","title":"A Study to Investigate the Use of Delayed Release Tablets for Colonic Delivery of Brilacidin in Healthy Volunteers","status":"COMPLETED","sponsor":"Innovation Pharmaceuticals, Inc.","startDate":"2020-01-06","conditions":"Healthy Volunteers","enrollment":9},{"nctId":"NCT04261179","phase":"PHASE4","title":"Study Comparing Lymphoseek® vs. Albumin Nanocolloid in Head and Neck, Melanoma and Breast Cancer","status":"UNKNOWN","sponsor":"Anna Cruceta","startDate":"2020-03","conditions":"Head Cancer, Neck Cancer, Melanoma","enrollment":30},{"nctId":"NCT02683421","phase":"PHASE1","title":"Evaluation of SC Injected Tc 99m Tilmanocept Localization in Active RA Subjects by SPECT and SPECT/CT Imaging","status":"COMPLETED","sponsor":"Navidea Biopharmaceuticals","startDate":"2016-07","conditions":"Rheumatoid Arthritis","enrollment":18},{"nctId":"NCT01138241","phase":"","title":"Tenofovir Renal Toxicity and Glomerular Filtration Rate (GFR) Validation","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2010-03","conditions":"Renal Function, HIV Infection","enrollment":700},{"nctId":"NCT02509585","phase":"PHASE2","title":"A Trial of Comparing the Pathology Status of Lymphoseek®-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection","status":"TERMINATED","sponsor":"Cardinal Health 414, LLC","startDate":"2016-01","conditions":"Uterine Cervical Neoplasms","enrollment":18},{"nctId":"NCT01982123","phase":"NA","title":"SPECT/CT in Measuring Lung Function in Patients With Cancer Undergoing Radiation Therapy","status":"COMPLETED","sponsor":"University of Washington","startDate":"2014-01-17","conditions":"Lung Carcinoma, Malignant Neoplasm","enrollment":12},{"nctId":"NCT02589366","phase":"PHASE1","title":"Lymphoseek as Lymphoid Tissue Targeting Agent in Patients With Cancer of the Endometrium","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2015-11","conditions":"Endometrial Cancer","enrollment":2},{"nctId":"NCT03199560","phase":"PHASE4","title":"Tilmanocept vs Sulfur Colloid in Sentinel Lymph Node Biopsy","status":"UNKNOWN","sponsor":"Memorial Health University Medical Center","startDate":"2017-06-22","conditions":"Sentinel Lymph Node Biopsy, Breast Cancer","enrollment":86},{"nctId":"NCT02450279","phase":"NA","title":"Scintigraphic Comparison of Lung Deposition With Two Nebulizers During Invasive Mechanical Ventilation","status":"TERMINATED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2016-03","conditions":"Post-operative Neurosurgery","enrollment":20},{"nctId":"NCT00541190","phase":"NA","title":"Absorptive Clearance in the Cystic Fibrosis Airway","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2007-10","conditions":"Cystic Fibrosis","enrollment":21},{"nctId":"NCT01034514","phase":"EARLY_PHASE1","title":"4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy","status":"TERMINATED","sponsor":"Billy W. Loo Jr.","startDate":"2009-12","conditions":"Lung Cancer","enrollment":35},{"nctId":"NCT02857608","phase":"PHASE2","title":"A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus","status":"WITHDRAWN","sponsor":"Cardinal Health 414, LLC","startDate":"2016-09","conditions":"Anal Cancer","enrollment":""},{"nctId":"NCT02429817","phase":"NA","title":"Tomographic Comparison of Aerosol Lung Distribution With Two Nebulizers Through a High Flow Nasal Cannula","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2015-04","conditions":"Healthy","enrollment":6},{"nctId":"NCT02201420","phase":"PHASE2","title":"Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT","status":"COMPLETED","sponsor":"Navidea Biopharmaceuticals","startDate":"2014-09","conditions":"Kaposi's Sarcoma","enrollment":5},{"nctId":"NCT01879488","phase":"NA","title":"Effect of Ventilation Mode on Lung Deposition of a Radiolabeled Aerosol During Mechanical Ventilation: Barometric Versus Volumetric","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2013-07","conditions":"Post-operative Neurosurgery","enrollment":19},{"nctId":"NCT02298101","phase":"NA","title":"Comparison of Lung Deposition With the Aeroneb Solo Adapter and a Standard Jet Nebulizer by SPECT-CT","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2014-09","conditions":"Healthy","enrollment":6},{"nctId":"NCT00911326","phase":"PHASE3","title":"Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"Navidea Biopharmaceuticals","startDate":"2009-05","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":101},{"nctId":"NCT01106040","phase":"PHASE3","title":"Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes","status":"COMPLETED","sponsor":"Navidea Biopharmaceuticals","startDate":"2010-06","conditions":"Breast Cancer, Melanoma","enrollment":163},{"nctId":"NCT00671918","phase":"PHASE3","title":"Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma","status":"COMPLETED","sponsor":"Navidea Biopharmaceuticals","startDate":"2008-04","conditions":"Breast Cancer, Melanoma","enrollment":186}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[{"date":"20250326","type":"ORIG","sponsor":"CURIUM","applicationNumber":"ANDA215146"}],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Tc-99m Pentetate","genericName":"Tc-99m Pentetate","companyName":"NYU Langone Health","companyId":"nyu-langone-health","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tc-99m Pentetate is a radiopharmaceutical that binds to transferrin in the blood and is filtered by the kidneys, allowing visualization of renal function and urinary tract anatomy via nuclear imaging. Used for Renal imaging and assessment of glomerular filtration rate, Detection of renal obstruction and urinary tract imaging, Evaluation of renal transplant function.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}